Spire Corporation Receives FDA Clearance To Market Nanocrystalline, Silver Coated, Long-Term Dialysis Catheters

Spire Corporation (Nasdaq: SPIR) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market silver coated hemodialysis catheters. The nanocrystalline, lubricious silver coating may reduce bacterial colonization on the catheter for up to two months, as demonstrated in clinical testing. The coating will be offered on Spire's XpressO(R) and RetrO(R) silicone catheter lines under the tradenames XpressO Silver(TM) and RetrO Silver(TM); both are split-tip chronic dialysis catheters.

Back to news